US Patent

US12364691 — Methods for treating pancreatic cancer using combination therapies

Method of Use · Assigned to Ipsen Biopharm Ltd · Expires 2033-06-12 · 7y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods for treating pancreatic cancer using liposomal irinotecan (MM-398) alone or in combination with other therapeutic agents.

USPTO Abstract

Provided are methods for treating pancreatic cancer in a patient by administering liposomal irinotecan (MM-398) alone or in combination with additional therapeutic agents. In one embodiment, the liposomal irinotecan (MM-398) is co-administered with 5-fluorouracil and leucovorin.

Drugs covered by this patent

Camptosar (Irinotecan Hydrochloride) · Pfizer

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1848`	—	Camptosar

Patent Metadata

Patent number: US12364691
Jurisdiction: US
Classification: Method of Use
Expires: 2033-06-12
Drug substance claim: No
Drug product claim: No
Assignee: Ipsen Biopharm Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.